IMV, Merck in Phase 2 Clinical Trial
Halifax-based Immunovaccine Inc., a clinical-stage immuno-oncology company, has announced that its main drug candidate for battling cancer will go through a Phase 2 clinical trial.
The publicly listed company said this week that its DPX-Survivac cancer vaccine candidate and a product of the New Jersey-based pharma giant Merck will be the subject of a Phase 2 trial at the Princess Margaret Cancer